

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Dapagliflozin for treating heart failure with reduced ejection fraction ID1656

Final Stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • AstraZeneca (dapagliflozin) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Arrhythmia Alliance • Atrial Fibrillation Association • Blood Pressure UK • British Cardiac Patients Association • Cardiomyopathy UK • Cardiovascular Care Partnership • HEART UK • Muslim Council of Britain • Network of Sikh Organisations • Pumping Marvellous Foundation • Somerville Foundation • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British and Irish Hypertension Society • British Association for Nursing in Cardiovascular Care • British Cardiovascular Society • British Geriatrics Society • British Heart Foundation • British Heart Rhythm Society • British Nuclear Cardiology Society • British Society for Heart Failure • British Society of Cardiovascular Imaging • King's Fund • National Heart and Lung Institute • Nuffield Trust • Primary Care Cardiovascular Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • Accord (bisoprolol, captopril, enalapril, eplerenone, hydralazine, irbesartan, ivabradine, lisinopril, losartan, nebivolol, olmesartan, perindopril, ramipril, spironolactone, telmisartan, valsartan) • Advanz (hydralazine, nebivolol) • Aspire (eplerenone, ivabradine) • AstraZeneca (lisinopril) • Aurobindo pharma (bisoprolol, candesartan, carvedilol, enalapril, irbesartan, lisinopril, losartan, nebivolol,

Final stakeholder list for the proposed technology appraisal of dapagliflozin for treating heart failure with reduced ejection fraction ID1656

Issue date: March 2020

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • • Royal College of Emergency Medicine • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Cardiological Science & Technology • Society for Vascular Nurses • Society for Vascular Technology • UK Clinical Pharmacy Association • Vascular Society of Great Britain and Ireland <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Bracknell and Ascot CCG • NHS South Devon and Torbay CCG • Welsh Government 	<ul style="list-style-type: none"> olmesartan, perindopril, quinapril, ramipril, valsartan) • Boehringer Ingelheim (telmisartan) • Brown and Burk (irbesartan, lisinopril, losartan, ramipril) • Consilient health (candesartan, eplerenone, irbesartan, losartan, perindopril, telmisartan) • Daiichi Sankyo (olmesartan) • Dexcel pharma (enalapril, losartan, valsartan) • Glenmark pharma (nebivolol, olmesartan, perindopril, telmisartan) • Lupin Healthcare (irbesartan, quinapril) • Martindale pharma (captopril) • Menarini (nebivolol) • Merck Sharp & Dohme (bisoprolol, enalapril, losartan) • Mylan (bisoprolol, candesartan, enalapril, eplerenone, eprosartan, hydralazine, lisinopril, losartan, olmesartan, perindopril, valsartan) • Novartis (sacubitril valsartan, valsartan) • Pfizer (eplerenone, quinapril, spironolactone) • Sandoz (bisoprolol, candesartan, losartan, ramipril) • Sanofi (irbesartan, ramipril, spironolactone) • Servier laboratories (arginine, ivabradine, perindopril) • Takeda (azilsartan, candesartan) • Thame laboratories (captopril) • Wockhardt (ramipril) • Zentiva (eplerenone, irbesartan, ivabradine, ramipril) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Society for Cardiovascular Research • Cardiac and Cardiology Research Dept, Barts • Circulation Foundation • Cochrane Heart Group

Final stakeholder list for the proposed technology appraisal of dapagliflozin for treating heart failure with reduced ejection fraction ID1656

Issue date: March 2020

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> • Cochrane Hypertension Group • Cochrane Vascular • European Council for Cardiovascular Research • Genomics England • Heart Research UK • MRC Clinical Trials Unit • National Centre for Cardiovascular Preventions and Outcomes • National Institute for Health Research • Wellcome Trust <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

Final stakeholder list for the proposed technology appraisal of dapagliflozin for treating heart failure with reduced ejection fraction ID1656

Issue date: March 2020

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.